CPHI 2026 – 23/07/2026
PCI Drug-Device 28/05/2026

Current Edition

ramusmedical
Regional News

Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses

Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering a s...
Continue Reading →
Regional News

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris ...
Continue Reading →
Regional News

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes m...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026